Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07850076 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CTX460 in Adults With Emphysema Associated With Severe Alpha-1 Antitrypsin Deficiency (AATD)

StatusNot Yet Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
A Study of CTX460 in Adults with Emphysema Associated with Severe Alpha-1 Antitrypsin Deficiency (AATD).
Trial Details
NCT Number NCT07850076
Lead Sponsor CRISPR Therapeutics
Conditions
(from sponsor)		 Alpha-1 Antitrypsin Deficiency (AATD)
Related terms alpha 1-Antitrypsin Deficiency
Enrollment 68 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov